Isomorphic Labs Raises $5B Series C to Push AI-Designed Drugs Toward Trials
Isomorphic Labs, Alphabet's AI drug-discovery company, announced on Nov 17 a $5 billion Series C financing round co-led by Greenoaks and Sequoia Capital, with the funds going to advance its AI drug-design engine IsoDDE and move its first drug candidates toward clinical trials.

What happened
The round was oversubscribed and co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz and several other new investors joining and Alphabet making a further significant investment; every existing investor returned, including Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund. The company did not disclose a valuation.
Isomorphic Labs was spun out of Google DeepMind in 2021 and is headquartered in London, led by DeepMind co-founder Sir Demis Hassabis as CEO. The company said its drug-design engine IsoDDE unifies a suite of foundational simulation AI models spanning multiple therapeutic areas and drug modalities, searching chemical space to design and refine molecules while proprietary agents navigate and reason over complex biological systems. The company reported positive preclinical results from its wholly owned oncology and immunology programs and from partnered programs, setting the stage for clinical entry.
In the announcement, Hassabis said the drug design engine is generating molecules with unprecedented precision and speed, and that the round will accelerate building foundational biology models, deepening understanding of systemic disease and driving the first therapeutic programs toward clinical trials.
Key facts
- Round: $5 billion Series C, oversubscribed, co-led by Greenoaks and Sequoia Capital
- Investors: Andreessen Horowitz and other new investors joined; Alphabet made a significant further investment; all existing investors returned, including Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund
- Valuation: The company did not disclose a valuation for the round
- Engine: IsoDDE is the company's proprietary drug-design engine, a suite of foundational simulation AI models spanning multiple therapeutic areas and drug modalities
- Progress: Wholly owned oncology and immunology programs and partnered programs reported positive preclinical results; human trials have not yet begun
- Previous round: The previous round was a $2.1 billion Series B announced May 12, 2026, led by Thrive Capital
- Partners: Partners listed on the company's website include Novartis, Eli Lilly and Johnson & Johnson
- Use of proceeds: Proceeds will fund further development of IsoDDE, expansion into new areas of biology, a partner ecosystem for mechanistic disease biology, and AI-first translational and clinical development infrastructure
Why it matters
The $5 billion Series C comes about six months after a $2.1 billion Series B, and the money is aimed at moving AI-designed drug candidates into human trials; the company has not yet begun human trials, so clinical entry for its first candidates is the round's next test.
CompaniesGoogle
Grab todayOpenAI Codex for Students: $100 in Free CreditsHIMIAO Picks →Follow HIMIAO Horizon
No sign-up · Unsubscribe any timeNotifications
A ping on your phone or computer when the brief is out. No email needed.
Comments
Related
- Oct 8Isomorphic Labs in Talks at a $40–50B Valuation; No Drug Yet in Human Trials
- Nov 13Nonprofits Sue Five AI Giants, Seeking a Halt to Frontier Model Development
- Nov 8Alphabet Discloses About $548 Million Qualcomm Stake Built in Q3
- Oct 29Alphabet Q3: Cloud Revenue Doubles as Capex and Cash Flow Diverge
- Oct 29Microsoft Fiscal Q1 2027: Azure Revenue Disclosed at $33.2 Billion for the First Time
Today
Nov 19 Thursday- Brief
- GitHubGitHub Weekly Vol.6: 7 Projects Worth a Look This Week
Tested or read — weeklyAll →
- Quiz
- Call
Latest news
All →- Nov 19MAI Code 2 vs Claude Opus 5.5 and GPT-6.1 Sol: $0.50 Input vs $4, Promo Price Until May 2027
- Nov 18Study: Frontier Models Can Be Tricked Into Marking Civilian Targets
- Nov 18Nvidia Reaffirms Open-Source Strategy, Hugging Face Deal on Track
- Nov 17Klarna Launches AI Assistant That Shops, Books and Runs Errands
- Nov 18Palo Alto to Buy Applied Compute for $4.5 Billion in All-Stock Deal
- Nov 18NGINX2Root Exposed: Five 9.2-Severity Flaws Let Attackers Run Code on Nginx Without Logging In
™